NCT06665217Not yet recruitingPhase 2
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Source: ClinicalTrials.gov · Last updated 14 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 28 Oct 2024
- Start date
- 24 Sept 2025
- Primary completion date
- Jan 2029
- Lead sponsor
- Navy General Hospital, Beijing
- NCT number
- NCT06665217
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From 24 Sept 2025 to the primary completion date, Jan 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.
Other illness
- Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.
Other
- Pregnant or lactating women
Who the study is looking for
- Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;
- Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
- Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted;
- Patient is willing and able to adhere to the study visit schedule and other protocol requirements;
- Patient has not received chemotherapy previously.
- Anticipated life expectancy at least 3 months
Age in the registry: 14 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.